Gynecologic Cancer

Seeing a young man ringing the bell surrounded by family reminded me of the incredible support I received during ovarian cancer, too.

Postmenopausal patients with ovarian or endometrial cancer who received conjugated equine estrogen may have increased mortality rates.

The FDA has approved several treatments for patients with solid tumors. Here are five recently approved treatments.

When compared with unvaccinated patients, HPV vaccines were associated with lower rates of HPV-related cancer for people younger than 40.

Most patients with locally advanced vulvar cancer who received chemotherapy and IMRT experienced a disappearance of their cancer.

Ignoring fear and anxiety only allows them to grow until they explode into a full-blown anxiety attack. It’s okay to be scared about cancer progression.

Radiation without chemotherapy was sufficient in treating locally recurrent endometrial cancer, allowing for patients to skip chemo-related side effects.

Adding Keytruda to chemotherapy with or without radiotherapy did not improve disease-free survival in newly diagnosed high-risk endometrial cancer.

This is the poem I wrote to help myself cope with my new diagnosis. It served as a reminder that I was resilient.

The Food and Drug Administration approved Tivdak for metastatic cervical cancer that progressed on or after chemotherapy.

Research has found simple hysterectomy to not be inferior to radical hysterectomy among patients with low-risk cervical cancer.

Even after surgery and chemotherapy, I make sure to shine through cancer and any fear that stares at me.

Since January 2024, the Food and Drug Administration has approved several treatments and combinations for solid tumors.

When I received a diagnosis of uterine cancer, I felt like I was falling into Wonderland, just like Alice.

The Food and Drug Administration granted a full approval to Elahere for the treatment of certain patients with platinum-resistant gynecologic cancers.

My genetic testing covered 648 gene variants. Of course, researchers only know the significance of a fraction of those variants.

Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.

“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer.

The FDA granted a Fast Track Designation to RC88, a novel antibody-drug conjugate, to treat patients with platinum-resistant gynecologic cancers.

Nearly 40% of patients who received treatment for cervical cancer were still being prescribed outpatient opioids for pain management six months later, according to recently published study findings.

The Food and Drug Administration approved Keytruda plus chemoradiotherapy for stage 3-4A cervical cancer.

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy.

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.